FDA
- Status: approved
🇺🇸 Meningococcal ACWY in United States
2 US adverse-event reports
Marketing authorisation
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 20 April 2025 – 20 April 2026
- Total reports: 2
Most-reported reactions
- Monoclonal Immunoglobulin Increased — 1 report (50%)
- Plasma Cell Myeloma Recurrent — 1 report (50%)
Meningococcal ACWY in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Meningococcal ACWY approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Meningococcal ACWY in United States?
Canadian Immunization Research Network is the originator. The local marketing authorisation holder may differ — check the official source linked above.